7. Bibliographie

  1. Akla B, Monteil J, Paraf F, Sturtz F, Rigaud M. A new orthopctic model of human breast cancer in immunocompetent rats. Anticancer Research, 2003,23 :3761-3766
  2. Allouche M, Delbruck HG, Klein B, Masse R, Matar A, Morin M, Lafuma J, Jasmin C. Malignant bone tumours induced by a local injection of colloidal radioactive 144Cerium in rats as a model for human osteosarcomas. Int J Cancer. 1980 Dec 15;26(6):777-82
  3. Bailey DL, Zito F, Gilardi MC, Savi AR, Fazio F, Jones T. Performance comparison of a state-of the-art neuro-SPET scanner and a dedicated neuro-PET scanner. Eur J Nucl Med. 1994 May;21(5):381-7.
  4. Barbaris E, Kronauge JF, Cohen D et al Characterization of P-glycoprotein transport and inhibition in vivo Cancer Res 1998 Jul;58:276-282
  5. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002 Sep;8(9):2766-74.
  6. Berger F, Lee YP, Loening AM, Chatziioannou A, Freedland SJ, Leahy R, Lieberman JR, Belldegrun AS, Sawyers CL, Gambhir SS. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1225-36.
  7. Blankenberg FG, Strauss HW. Will imaging of apoptosis play a role in clinical care? A tale of mice and men.Apoptosis. 2001 Feb-Apr;6(1-2):117-23.
  8. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997 Nov 27;390(6658):404-7.
  9. Boisgard R, Vincent-Naulleau S, Leplat JJ, Bouet S, Le Chalony C, Tricaud Y, Horak V, Geffrotin C, Frelat G, Tavitian B. A new animal model for the imaging of melanoma: correlation of FDG PET with clinical outcome, macroscopic aspect and histological classification in Melanoblastoma-bearing Libechov Minipigs. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):826-34.
  10. Boren EL Jr, Delbeke D, Patton JA, Sandler MP. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies. Eur J Nucl Med. 1999 Apr;26(4):379-87.
  11. Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, Chauffert B, Corone C, Courbon F, Devillers A, Foehrenbach H, Lumbroso JD, Mazselin P, Montravers F, Moretti JL, Talbot JN; FNCLCC PET-Scanning Committee. Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Bull Cancer. 2003 Aug;89 Suppl 1:S84-91.
  12. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med. 2003 Jun;44(6):930-42.
  13. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003 Sep;44(9):1426-31.
  14. Cailleau R,Young R,Olive M and Reeves WJ,Jr. Breast tumor cell lines from pleural effusions.J Natl Cancer Inst 53 :661-74,1974
  15. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 1983;105(1):20-3.
  16. Charissoux JL, Grossin L, Leboutet MJ, Rigaud M. Treatment of experimental osteosarcoma tumors in rat by herpes simplex thymidine kinase gene transfer and ganciclovir. Anticancer Res. 1999 Jan-Feb;19(1A):77-80.
  17. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995 Sep;36(9):1625-32.
  18. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med. 1996 Mar;37(3):502-6.
  19. Chatziioannou AF, Cherry SR, Shao Y, Silverman RW, Meadors K, Farquhar TH, Pedarsani M, Phelps ME. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med. 1999 Jul;40(7):1164-75.
  20. Chung, J.K.; Chang, Y.S.; Lee, Y.J.; et al. The effect of tumor size on F-18-labeled Chung JK, Chang YS, Lee YJ, Kim YJ, Jeong JM, Lee DS, Jang JJ, Lee MC. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med. 1999 Oct;13(5):303-8.Nucl. Med. 13:303-8; 1999
  21. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med. 1992 Jun;33(6):1191-9.
  22. De Dreuille O. Tomographie par Emission de Positons. Aspects techniques. Diplôme Technique de l’Ecole d’application du Service de Santé des Armées. Option : Recherche et Techniques de laboratoires.1999
  23. De Dreuille O, Maszelin P, Foehrenbach H, Bonardel G et Gaillard JF. Principe et technique de la tomographie par émission de positons (TEP). Encycl Med Chir (Editions Scientifiques et Médicales Elsevier SAS, Paris), Radiodiagnostic- Principes et techniques d’imagerie, 35-310-A-10, 2002, 22p.
  24. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography.Eur Urol. 2002 Jul;42(1):18-23.
  25. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience.Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1283-8.
  26. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003 Mar;44(3):331-5.
  27. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Sauer B, Rigaud M. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastasis in osteosarcoma. Accepted in Mol. Ther. 2004
  28. Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. Radiographics. 2000 Jan-Feb;20(1):59-66.
  29. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001 May;42 (5 Suppl):1S-93S.
  30. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F. Bone remodelling and tumour grade modifications induced by interactions between bone and Swarm rat chondrosarcoma. Histol Histopathol 2002 ; 17 : 1103-111
  31. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998 Oct;114(4):1105-11.
  32. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, Kahn B, van Kaick G.Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med. 1994 Nov;35(11):1842-50.
  33. Haberkorn U, Reinhardt M, Strauss LG, Oberdorfer F, Berger MR, Altmann A, Wallich R, Dimitrakopoulou A, van Kaick G. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med. 1992 Nov;33(11):1981-7.
  34. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994 Aug;35(8):1308-12.
  35. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001 Mar 1;61(5):1781-5.
  36. Heiss WD, Wienhard K, Graf R, Lottgen J, Pietrzyk U, Wagner R. High-resolution PET in cats: application of a clinical camera to experimental studies. J Nucl Med. 1995 Mar;36(3):493-8.
  37. Hernigou P, Thiery JP, Benoit JP, Voisin MC, Leroux P, Hagege G, Delepine G, Goutallier D. Etude expérimentale sur l’ostéosarcome d’une chimiothérapie locale diffusant à partir du ciment acrylique chirurgical et du plâtre. Rev Chir Orthop Reparatrice Appar Mot. 1987;73(7):517-29.
  38. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol. 2000 Oct;27(7):643-6.
  39. Keyes JW Jr. SUV: standard uptake or silly useless value?J Nucl Med. 1995 Oct;36(10):1836-9.
  40. Kim KT, Black KL, Marciano D, Mazziotta JC, Guze BH, Grafton S, Hawkins RA, Becker DP. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med. 1990 Jun;31(6):965-9.
  41. Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, Jacobs A, Goble RN, Graf R, Wienhard K, Heiss WD. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging. 2003 May;30(5):737-47
  42. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992 Nov;33(11):1972-80.
  43. Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-6
  44. Kunze WD, Baehre M, Richter E. PET with a dual-head coincidence camera: spatial resolution, scatter fraction, and sensitivity. J Nucl Med. 2000 Jun;41(6):1067-74.
  45. Lausson S, Maurel G, Kerrou K, et al. Imagerie au 18FDG des tumeurs expérimentales du petit animal de laboratoireà l’aide d’une gamma-caméra hybride optimisée pour la scintigraphie chez l’homme. Med. Nucl. (Imagerie Foncionnelle et Métabolique); 25:371-379 ; 2001
  46. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999 Jan;26(1):22-30.
  47. Melloni B, Monteil J, Bertin F, Ducloux T, Gaillard S, Vincent F, Vergnenegre A, Laskar M, Vandroux JC, Bonnaud F. Intérêt du 18FDG-TEDC dans l’évaluation du cancer bronchique opérable Rev Mal Respir, 2001, 18 :599-606
  48. Melloni B, Monteil J, Vincent F, Bertin F, Gaillard S, Ducloux T, Verbeke S, Maubon A, Vandroux JC, Bonnaud F. Assessment of 18F-FDG Dual-Head gamma camera in asbestos lung diseases. Accepté dans European Respiratory Journal 2004,
  49. Monteil J, Jacob T, Vandroux JC, Mundler O. Réalisation pratique d’un examen TED/TDM : de l’indication au compte-rendu. Méd. Nucl. (Imagerie fonctionnelle et métabolique) 2004 ; 28 :189-203.
  50. Monteil J, Melloni B. La fusion des images de tomographie à émission de positons (TEP) et de tomodensitométrie. Applications en pathologie maligne thoracique. Accepté pour publication dans La lettre du pneumologue. 2004.
  51. Nuutinen J, Jyrkkio S, Lehikoinen P, Lindholm P, Minn H. Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography.Radiother Oncol. 1999 Sep;52(3):225-32.
  52. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7.
  53. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90.
  54. Phelps ME, Hoffman EJ, Huang SC, Kuhl DE. ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals. J Nucl Med. 1978 Jun;19(6):635-47.
  55. Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Kruger A, Schwaiger M, Senekowitsch-Schmidtke R. O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1039-46.
  56. Romer W, Schwaiger M. Positron Emission Tomography in Diagnosis and Therapy Monitoring of Patients with Lymphoma. Clin Positron Imaging. 1998 Mar;1(2):101-110.
  57. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.Lung Cancer. 2002 Feb;35(2):179-87.
  58. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Kluge R, Sabri O. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003 Apr;30(3):317-26.
  59. Townsend DW, Defrise M, Geissbuhler A, Spinks T, Jones T. Three-dimensional reconstruction for a multi-ring positron tomograph. Prog Clin Biol Res. 1991;363:139-54.
  60. Vuillez JP. Métabolisme glucidique des cellules tumorales : conséquence pour l’utilisation des radiopharmaceutiques analogues du glucose. Med Nucl. 1998;22:9-29.
  61. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, Bommer M, Leithauser F, Wawra E, Munzert G, Reske SN. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res. 2003 May 15;63(10):2681-7.
  62. Warburg O. On respiratory impairment in cancer cells. Science. 1956 Aug 10;124(3215):269-70
  63. Warburg O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309-14.
  64. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995 Jul;36(7):1301-6.
  65. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001 Sep;42(9):1412-7.